Evaluation of the Efficacy of Transcranial Direct Current Stimulation in Reducing Fatigue and Improving Quality of Life in Patients With Multiple Sclerosis: A Randomized Clinical Trial
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
European University of Madrid
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with multiple sclerosis defined according to the McDonald criteria (2017 revised version).
Age between 18 and 75 years.
No relapse in the last 2 months.
Fatigue experienced in the last 6 months, according to the Fatigue Severity Scale (FSS \> 4).
You may not be if
Patients who have not had stable pharmacological treatment in the last month.
Patients with contraindications to the use of tDCS, such as: defibrillator, pacemaker, brain stimulator, implanted intracranial metals, skull fractures or fissures, damaged skin or recent scars, epilepsy, pregnancy.
Patients who are undergoing or need to undergo immunosuppressive treatment for MS with Ocrelizumab, Rituximab, Lemtrada, or Mavenclad one week before or during the application of tDCS.
Patients with cognitive difficulties that prevent them from understanding the applied scales.
Patients who experience adverse effects from tDCS treatment.
Inability to remain in the study and complete the third cycle and/or the V3 assessment.
Clareo Health | Evaluation of the Efficacy of Transcranial Direct Current Stimulation in Reducing Fatigue and Improving Quality of Life in Patients With Multiple Sclerosis: A Randomized Clinical Trial
